Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

82.95USD
21 Mar 2019
Change (% chg)

$0.87 (+1.06%)
Prev Close
$82.08
Open
$82.10
Day's High
$83.17
Day's Low
$81.94
Volume
2,463,540
Avg. Vol
4,138,716
52-wk High
$83.17
52-wk Low
$52.83

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $176,050.70
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.47
Yield (%): 2.91

Financials

  MRK.N Industry Sector
P/E (TTM): 35.16 29.30 32.54
EPS (TTM): 1.84 -- --
ROI: 6.58 14.23 13.82
ROE: 12.28 15.46 15.25

UPS eyes in-home health services with U.S. vaccine project

LOUISVILLE, Ky. - United Parcel Service Inc wants to get beyond U.S. doorsteps with a new push into healthcare.

5:38am GMT

UPS eyes in-home health services with U.S. vaccine project

LOUISVILLE, Ky. - United Parcel Service Inc wants to get beyond U.S. doorsteps with a new push into healthcare.

5:08am GMT

FOCUS-UPS eyes in-home health services with U.S. vaccine project

LOUISVILLE, Ky., March 22 - United Parcel Service Inc wants to get beyond U.S. doorsteps with a new push into healthcare.

5:00am GMT

U.S. FDA approves Roche's small cell lung cancer treatment

March 18 Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb.

19 Mar 2019

Roche's Tecentriq notches win in breast cancer with U.S. approval

ZURICH Roche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a significant number of patients with triple-negative breast cancer, a development hailed by doctors as a promising advance in fighting the aggressive disease.

08 Mar 2019

UPDATE 2-Roche's Tecentriq notches win in breast cancer with U.S. approval

* Roche trails Bristol, Merck in immunotherapy sales (Adds comment from doctor about approval)

08 Mar 2019

French court dismisses damages claims against Merck over thyroid drug

LYON, France A court in the French city of Lyon threw out on Tuesday claims made by 4,113 plaintiffs for damages against Merck over changes to its thyroid drug Levothyrox.

05 Mar 2019

French court dismisses damages claims against Merck over thyroid drug

LYON, France, March 5 A court in the French city of Lyon threw out on Tuesday claims made by 4,113 plaintiffs for damages against Merck over changes to its thyroid drug Levothyrox.

05 Mar 2019

Versum unveils plan to fend off hostile takeover

United States based Versum Materials on Thursday unveiled a plan to prevent a hostile takeover in the face of an unsolicited $5.9 billion offer from Germany's Merck.

28 Feb 2019

UPDATE 1-Versum unveils plan to fend off hostile takeover

* Versum plan designed to stop outsider from taking control (Recasts with details of Versum's plan, adds Merck comment)

28 Feb 2019

Earnings vs. Estimates